Alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) affect 29 million people in the European Union. Patients with ASH and NASH may exhibit cognitive impairment, reducing their quality of life. Steatohepatitis induces cerebral alterations. It is not known if histological analysis could allow distinguishing ASH, NASH, and/or cirrhosis neuropathology and other entities. The aim of this work was to analyze a set of histopathological features characterizing the brain lesions due to ASH, NASH, and cirrhosis. We performed a histological study using hematoxylin and eosin staining and immunohistochemical techniques in cerebellum of 31 subjects who died with healthy liver (n ¼ 6), NASH (n ¼ 14), ASH (n ¼ 3), nonalcoholic cirrhosis (n ¼ 4), and alcoholic cirrhosis (n ¼ 4). We analyzed in cerebellum, as an early marker for brain injury: 1) vascular damage; 2) cerebellar atrophy and neurodegeneration in Purkinje layer; and 3) microglia and astrocytes activation in white matter and molecular layer. Patients with steatohepatitis have increased number of microtrombi in cerebellar parenchyma, neuronal loss in Purkinje layer and microglial and astrocyte activation in white matter and molecular layer. These alterations are stronger in patients with ASH than in those with NASH. These results provide a set of histopathological features in brain that may allow differentiation of steatohepatitis from other conditions.
INTRODUCTION
Liver diseases are extremely costly in terms of human suffering, general practitioner visits and hospitalizations, and premature loss of productivity. In 2013, 29 million people in the European Union were documented as suffering from a chronic liver disease (1) .
According to the World Health Organization (2), liver cirrhosis represents the main cause of death due to liver condition, producing 1.8% of all deaths in Europe (170 000 deaths per year) (2) . However, many patients with fatty liver disease (FLD), even before developing hepatic cirrhosis, may already present cognitive impairment (3) that reduces their quality of life and lifespan and increases the risk of developing hepatic cirrhosis and hepatocellular carcinoma, the primary malignancy of the liver and the third leading cause of cancer deaths worldwide, with over 500 000 people affected (4) .
The 2 main types of FLD are alcoholic liver disease and nonalcoholic fatty liver disease, both of which are characterized by variable deposition of lipids (>5%) in the hepatocytes (5) . A subsequent inflammatory reaction with ballooning of the hepatocytes results in alcoholic steatohepatitis (ASH) or nonalcoholic steatohepatitis (NASH) (5) . In its end stage, ASH or NASH may lead to fibrosis or cirrhosis (5) .
ASH is the most prevalent cause of advanced liver disease in Europe (6) , and cirrhosis is the leading cause of death due to alcohol among adults, representing $48% of the total deaths (7) .
NASH is a condition characterized by an excessive accumulation of fats in the liver of a patient without a history of alcohol abuse. It is etiologically associated mainly with obesity (8, 9) , diabetes (9, 10) , hyperlipidemia (9) , and insulin resistance (11) with features of the metabolic syndrome (12) .
Liver failure (mainly cirrhosis) affects brain function, leading to neurological and psychiatric alterations referred to as hepatic encephalopathy (13) . However, many patients with steatohepatitis may already present neuropsychiatric impairments before developing cirrhosis (3) . In addition, many studies reveal that the cerebellum is one of the first areas affected at early stages of chronic liver diseases (14) (15) (16) (17) . We therefore focus this study on the cerebellum as an early marker for brain injury, assuming that parallel changes will be happening in hippocampus or cerebral cortex at later stages.
Steatohepatitis, both nonalcoholic and alcoholic, and hepatic cirrhosis may induce lesions in the brain. However, it remains unclear if it is possible to differentiate the brain lesions due to these entities based on the presence of different histopathological features and/or from their relative quantitative importance. Moreover, other entities such as acquired hepato-cerebral degeneration (AHD), Alzheimer disease (AD), or ischemic-vascular dementia (IVD) can share some cerebral histopathological features with ASH or NASH, making its differentiation even more complicated.
The aim of this work was to analyze a set of histopathological features characterizing the brain lesions due to ASH, NASH, and cirrhosis. This could allow pathologists to distinguish ASH, NASH, and/or cirrhosis lesions from similar lesions present in other pathologies. To reach this aim, we performed a histological study using hematoxylin and eosin (H&E) staining and immunohistochemical techniques to identify parameters characterizing the cerebral alterations associated to different clinical entities due to liver pathology.
MATERIALS AND METHODS

Collecting Cases and Processing Tissue
Postmortem human brain samples were obtained from the Instituto de Medicina Legal y Ciencias Forenses (Valencia), Biobanco Hospital Universitario Fundaci on Alcorcon, Biobanco A Coruña and Biobanc Hospital Clinic IDIBAPS. Sections of human Cerebellum were collected from 31 recently deceased subjects with chronic liver disease diagnoses and matched controls (people with no liver disease and neurodegenerative diagnosis). Subjects presenting a history or evidence of AD or IVD were excluded from the study. For each case, we obtained authorization to collect the tissue for research use. Characteristics of the patients are detailed in the Table. Sections of cerebellum were fixed in 10% formalin for 96 hours at 4 C. Then, the samples were placed inside histology cassettes and processed for permanent paraffin embedding on a Leica ASP 300 tissue processor (Leica Microsystems, Wetzlar, Germany). Patients were classified into 5 categories: controls (n ¼ 6; mean age ¼ 69 6 3); NASH (n ¼ 14; mean age ¼ 47 6 1); ASH (n ¼ 3; mean age ¼ 51 6 9); nonalcoholic cirrhosis (NA cirrhosis; n ¼ 4; mean age ¼ 69 6 6); and alcoholic cirrhosis (A cirrhosis; n ¼ 4; mean age ¼ 60 6 3).
Cerebellum Histology and Immunohistochemistry
Five-lm-thick, paraffin-embedded sections were cut and mounted on coated glass slides. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 AR buffer EDTA pH 9.0 in a DAKO PT link (DAKO, Santa Clara, CA). The tissue sections were then processed with the Envision Flexþ kit (DAKO), blocking endogenous peroxidase activity for 5 minutes and then incubating with primary antibody. The reaction was visualized by Envision Flexþ horseradish peroxidase for 20 minutes and finally diaminobenzidine for 10 minutes. Sections were counterstained with Mayer's hematoxylin (DAKO, S3309, ready-to-use) for 5 minutes.
The primary antibodies used were anti-Iba1 as microglial marker (Wako, 019-19741; 1:300 for 30 minutes; Wako, Osaka, Japan), anti-GFAP as astrocyte marker (Dako, IR524, ready-to-use for 20 minutes), and anti VS38 as rough endoplasmic reticulum (rER) marker (Dako, M7077, 1:100 for 30 minutes). The analysis of Purkinje cell density and quantification of microthrombi number were performed using H&E (Dako, SM806).
Immunohistochemical quantification was performed using ImageJ (1.48v). For analysis of microglial and astroglial activation, the areas of interest were selected and photographed using Pannoramic viewer (v. 1.15; 3DHISTECH, Budapest, Hungary). Using the "auto local threshold" and "analyze particle" functions, the intensity thresholds and size filter were applied. To measure the perimeter of microglia, the Bernsen method was used and 2000-20 000 size filter was applied. For each case at least 30-40 cells were quantified. The results were then converted from pixels to micrometers. For GFAP staining no size filter was applied. For each case at least 10 fields (56Â) were quantified. The result was expressed as percentage of total stained area.
Analysis of Cerebellar Atrophy, Neuronal Density, and Microthrombi Numbers
For quantification of neuronal density in Purkinje layer of cerebellum, H&E-stained sections were used and 10-15 fields (7Â) for each case were quantified. Purkinje cells were manually counted using ImageJ and results expressed as cell/ mm of Purkinje layer. Cerebellar atrophy in depths of sulci was measured using the "measure distance" tool in Pannoramic viewer software (v. 1.15; 3DHISTECH) and results were expressed in micrometers. For quantification of microthrombi number, H&E-stained sections were used and the entire cerebellar sections were quantified using Pannoramic viewer Software (v. 1.15; 3DHISTECH). The number of microthrombi was manually counted and results expressed as number of microthrombi/cm 2 .
Statistical Analysis
Results are expressed as mean 6 SEM. Data were analyzed by 1-way ANOVA followed by Tukey post hoc test; p < 0.05 was considered significant difference.
RESULTS
The number of microthrombi is increased in patients with chronic liver disease, especially in ASH. All groups of patients showed vascular injury in cerebellum compared with controls ( Fig. 1) . The highest number of microthrombi was found in the ASH (21 6 3 microthrombi/cm 2 ; p < 0.0001) and in both cirrhotic groups (nonalcoholic cirrhosis: 15 6 3 microthrombi/cm 2 ; p < 0.001; alcoholic cirrhosis: 17 6 2 microthrombi/cm 2 ; p< 0.01) compared with controls (2 6 1) (Fig. 1A, B) . NASH patients showed 10 6 1 microthrombi/ cm 2 , which was lower (p < 0.05) than in ASH patients but higher (p < 0.01) than in controls (Fig. 1B) . Cerebellar microvascular damage is also reflected by the dilatation of the Virchow-Robin space, as shown in Figure 1C (blue arrow).
Neuronal loss and neuroinflammation were higher in cerebellum of patients with ASH and cirrhosis than in patients with NASH. H&E staining revealed neuronal loss in Purkinje layer in both groups of patients with steatohepatitis and cirrhosis ( Fig. 2A-C) . Patients with NASH displayed a significant decrease of Purkinje neurons (6.0 6 0.2 cells/mm; p < 0.001) compared with control subjects (7.5 6 0.3 cells/mm) (Fig. 2C ). Neuronal loss was even higher in patients with ASH (4.8 6 0.3 cells/mm; p < 0.0001) and in patients with nonalcoholic and alcoholic cirrhosis (4.6 6 0.3 cells/mm and 4.5 6 0.3 cells/mm, respectively) compared with both control subjects (p < 0.0001) and patients with NASH (p < 0.001 and p < 0.05, respectively) ( Fig. 2C) . No differences between patients with ASH and both groups of cirrhosis were observed (Fig. 2C ). Neuronal loss observed in these patients was related to a subtle and localized atrophy observed in most of patients, mainly with cirrhosis ( Fig. 2D, E) . In fact, a significant atrophy in depths of sulci ( Fig. 2D ) was observed in cerebellum of patients with nonalcoholic and alcoholic cirrhosis (832 6 19 lm and 817 6 24 lm; p < 0.05) compared with control subjects (977 6 32 lm) and NASH patients (953 6 22 lm). No atrophy was observed in crests of gyri and superior vermis (data not shown). Figure 2F shows a representative image of an ASH patient with damaged neurons presenting loss or inactivation of ribosomes and rER loss (red arrow), compared with controls (blue arrow, Fig. 2G ). rER was stained with VS38, an antibody that recognizes an intracellular antigen termed p63, abundant in rER.
Patients with ASH or cirrhosis but not patients with NASH showed microglial activation in white matter of cerebellum (Fig. 3) . Microglial cells were activated in patients with ASH and in both groups of cirrhosis, showing hypertrophied nuclei and shorter ramifications (Fig. 3A) . These morphological changes were reflected in a significant decrease of microglia perimeter in white matter of patients with ASH (184 6 5 mm; p < 0.01), nonalcoholic cirrhosis (171 6 6 mm; p < 0.001), and alcoholic cirrhosis (170 6 5 mm; p < 0.001) compared with controls (218 6 7 mm) or NASH patients (204 6 4 mm), who were not significantly different from controls (Fig. 3C) .
Representative images and quantitative data for the molecular layer are shown in Figure 3B , D. In this area, subjects with NASH, ASH, and both groups of cirrhosis showed reduced microglia perimeter (199 6 5 mm; 177 6 7 mm; 156 6 8 mm; and 164 6 7 mm, respectively; p < 0.0001) compared with controls (269 6 12 mm) (Fig. 3B, D) . Microglial activation was stronger in nonalcoholic cirrhotic (p < 0.05) and alcoholic cirrhotic (p < 0.01) patients that in NASH (Fig. 3D) . In NASH patients, therefore, microglia were activated in the molecular layer but not in white matter, whereas in patients with ASH or cirrhosis they were activated in both areas.
We also quantified astrocytes activation in white matter by measuring the area covered by GFAP staining. Figure 4A , B show that patients with ASH have the highest percentage of GFAP staining (58 6 1%) compared with the other 4 groups (p < 0.001). Moreover, the content of GFAP in NASH patients (49 6 1%) also differed from controls (39 6 1%; p < 0.0001) and nonalcoholic and alcoholic cirrhotic patients (38 6 2% and 41 6 1%; p < 0.0001) (Fig. 4B) .
Neuroinflammation in molecular layer was also reflected in altered Bergmann glia, a specialized type of astrocyte. A representative photo of molecular layer of an ASH patient stained with GFAP is shown in Figure 4C . Bergmann glia was damaged, with fragmented and irregular morphology (red rectangle). Similar alterations were observed in patients with NASH and cirrhosis (data not shown).
DISCUSSION
Our results show that steatohepatitis (alcoholic or nonalcoholic) induces a specific set of lesions in cerebellum that would allow differentiation from other pathologies. The main histopathological features found (summarized in Fig. 5 ) included increased number of microthrombi in cerebellar parenchyma, neuronal loss in Purkinje layer, microglial and astrocyte activation in white matter, and Bergmann glia alteration in molecular layer. A main finding is that these alterations were higher in patients with ASH than in those with NASH (Fig. 5) . No differences between alcoholic and nonalcoholic cirrhosis were observed.
Some lesions described here, such as cerebellar neurodegeneration and alteration in glial cells, have been reported in a rare neurological syndrome named "acquired hepatocerebral degeneration" (AHD), described for the first time in 1914 (18) and characterized by Parkinsonism, ataxia, and other movement disorders (19) . AHD is estimated to occur in around of 1%-2% of patients with chronic liver diseases, mainly cirrhosis (20) . Here, we show that this set of lesions is already present in patients with steatohepatitis, even before reaching cirrhosis, and that seem to be more frequent than expected. Furthermore, the alterations described show some histopathological differences with those observed in AHD, which are also characterized by laminar neuronal necrosis and cortical gliosis (21) .
Patients with cirrhosis show slightly higher microglial activation than patients with ASH. However, activation of astrocytes and GFAP content is lower in cirrhotic patients than in patients with ASH. These results are in agreement with previous studies showing a downregulation of GFAP in cirrhotic patients, especially in those with patients with hepatic encephalopathy (22, 23) , which seems to be due to the increased ammonia and/or TNFa levels (24, 25) .
Some neurodegenerative diseases such as AD, or vascular diseases such as IVD or atherosclerosis, may share some cerebral histopathological features with ASH or NASH making its differentiation more complicated. A number of morphological studies on brains of patients who died with AD report the presence of cerebellar atrophy, loss of Purkinje neurons and increased number of microglial cells and of astrocytes (26-28), but they do not report morphological reaction or activation of astrocytes and microglial cells activation or vascular damage as observed in this work. Neuronal loss and reactive gliosis have been also reported in white matter of patients with IVD and atherosclerosis (29, 30) but not microglial activation and Bergmann glia degeneration in molecular layer of these patients. These differences may allow distinguishing cerebellar lesions in ASH and NASH from those in AD, IVD, or atherosclerosis.
Another finding of the present study is the presence of vascular damage and relevant formation of microthrombi in cerebellum of patients with steatohepatitis, both alcoholic and nonalcoholic. This phenomenon is more important quantitatively in the ASH group than in NASH or cirrhosis groups. These results agree with reports showing that heavy alcohol consumption increases the risk of suffering vascular diseases (31, 32) . However, in chronic liver disease, vascular injury has been mainly studied in liver of patients with steatohepatitis (33) or cirrhosis (34), but its presence in brain of patients with steatohepatitis has been poorly studied. We show here that patients with ASH and NASH already present vascular damage in cerebellar parenchyma. The presence of vascular damage has been associated with neuroinflammation and cognitive impairment in patients with vascular dementia (35) and Binswanger disease (36) , or in hippocampus, basal ganglia, thalamus, or deep white matter of other pathologies associated with dementia (29, 30, 37) . A relationship between vascular damage and neuroinflammation in cerebellum of these patients remains unclear. The vascular damage in ASH and NASH could contribute to the neuroinflammatory and neurodegenerative response observed in this and other studies (22) .
The comparison of the histological alterations in cerebellum of patients with NASH, ASH, and cirrhosis (Fig. 5) showed the following: 1) vascular damage was stronger in patients with ASH than with cirrhosis and was milder in patients with NASH; 2) in white matter, microglial activation was observed in patients with ASH, was stronger in patients with cirrhosis, but it was absent in patients with NASH; 3) in the molecular layer, microglial activation was stronger in patients with ASH or cirrhosis, and there was also a milder activation of microglia in patients with NASH; 4) loss of Purkinje neurons was strong in patients with ASH or cirrhosis and was milder in patients with NASH; and 5) activation of astrocytes was high in patients with NASH and stronger in patients with ASH.
In parallel with microglia activation, Purkinje cell loss is higher in ASH and cirrhotic patients than in NASH patients, suggesting a possible direct role of microglia in this neurodegenerative process. Purkinje cells are vulnerable neurons that die during aging (38) . However, the reduced number of Purkinje neurons reported here cannot be due to an effect of age because the mean ages of NASH (47 6 1) and ASH (51 6 9) patients were lower than for controls (69 6 3) and nonalcoholic and alcoholic cirrhotic patients (69 6 6 and 60 6 3, respectively). Many recent studies show that microglia can remove not only dying or dead neurons but also live neurons, causing neuronal death (39) . ASH patients also showed more damaged neurons than control subjects, presenting loss or inactivation of ribosomes and rER loss (as shown by SV38 staining in Fig. 2F, G) . The neuronal loss in Purkinje layer was also related with macroscopic cerebellar atrophy, as shown in Figure 2D . Despite the fact that it was fairly subtle and, in many cases, localized, we found that cerebellar atrophy was maximal in depths of sulci of both groups of patients with cirrhosis.
No relevant presence of Alzheimer type II astrocytes was found in the present study. It has been proposed that Alzheimer type II astrocytes are a neuropathological feature of end-stage chronic liver failure and are mainly found in patients who died in hepatic coma (40) . In addition, Alzheimer type II astrocytes are more prominent in cortical areas, basal ganglia, and thalamic nuclei (23) , with a more subtle effect on Bergmann glia of cerebellum (41) . The lack of detection of Alzheimer type II astrocytes in our study may be due to the fact that we analyzed cerebellum from patients at early stages of liver disease (steatohepatitis) or from cirrhotic patients, most of whom did not die as a result of hepatic coma but from other causes, as shown in the Table. Patients with NASH may show mild cognitive impairments if the levels of peripheral inflammatory markers and ammonia are high enough (3) . The presence of neuroinflammation in the steatohepatitis stage (both alcoholic and nonalcoholic) could contribute to the cognitive alterations described in patients with diabetes (42), obesity (43) , and NASH (3) .
It has been shown in animal models that peripheral inflammation is primarily responsible for induction of neuroinflammation and cognitive and motor impairment in rats with liver failure (44, 45) . Peripheral inflammation in patients with NASH, ASH, or cirrhosis may induce endothelial damage, which may lead to the formation of the microthrombi reported here, and facilitate the induction of neuroinflammation, which could be mediated by the infiltration of T lymphocytes in cerebellar meninges of these patients (22) . In fact, we have recently reported that patients with different grades of steatohepatitis showed infiltration of CD4 þ T lymphocytes in the meningeal space of cerebellum. This infiltration was associated with induction of neuroinflammation in the molecular layer and, later, in white matter of cerebellum (22) .
The present study has some limitations. First, this is a retrospective study and most of the samples were obtained from different biobanks. This implies that details identified at autopsy or information related to the clinical history of the patients (e.g. treatments, drugs, and/or the occurrence of Cerebellar Histopathology of Steatohepatitis infectious or inflammatory events) were not available to us, thus precluding the discussion of these parameters on the effects observed. In addition, the etiology for NASH cases was unknown, but we do not believe that this would have had an effect on the findings reported. In addition, the data on brain weight of the patients was not available and cannot be provided here. Finally, the number of ASH subjects analyzed (n ¼ 3) was small. Unfortunately, in spite of many efforts during the last 2 years, we have not been able to get more samples for this group. However, some of the effects reported for this group were already statistically significant compared with other groups (e.g. number of microthrombi, Purkinje neurons, and astrocyte activation), allowing us to conclude the differential effects on these parameters. In summary, we show that steatohepatitis (both alcoholic and nonalcoholic) induces vascular damage, neuroinflammation, and neurodegeneration in cerebellum, which is higher in patients with ASH. Together, these alterations may represent a clinical-pathological reflection of encephalopathy observed in patients with steatohepatitis (3, 42, 43) . Injury occurs mainly in vessels, with microthrombotic phenomena and at the level of the cerebellum, with loss of Purkinje cells. The inflammatory process leads to microglial proliferation and astroglial reaction. Lesions of the cerebral parenchyma are not usually specific for an etiology of toxic, infectious, or vascular origin; however, a set of lesions may correlate with the etiology. NASH and ASH display a set of lesions that seem to be related to each other, showing vascular lesions, proliferative/reparative inflammatory reaction, and cell death, which would be associated with the cognitive disorder observed in patients with steatohepatitis (3, 42, 43) .
NASH and ASH are becoming more frequent every day. The results reported provide a set of histopathological markers in brain that allow the pathologist to identify in autopsy studies in patients with chronic liver disease the "picture" of the histological alterations in cerebellum in NASH, ASH, and cirrhosis and to distinguish them from other conditions such as AHD or neurodegenerative diseases (such as AD) or vascular pathologies (such as atherosclerosis and IVD). Finally, these findings highlight the importance of detecting steatohepatitis at early stages to try to prevent the progression to worse pathological conditions such as liver cirrhosis and encephalopathy.
